Pear Therapeutics said this month that it closed a $64 million Series C round led by Temasek. The Boston-based company plans to use its newly-acquired funds to support the global commercialization of its reSET prescription digital therapeutics and fund its clinical pipeline, as well as buy up additional assets. Get the full story at our sister […]
peartherapeutics
Pear Therapeutics, Sandoz ink deal for prescription digital therapeutics
Pear Therapeutics revealed yesterday that it agreed to deal commercialization rights of its digital therapeutics to Novartis (NYSE:NVS) division Sandoz. The company’s reSET substance use disorder therapy became the first prescription digital therapeutic approved by the FDA in September last year. reSET-O, a digital therapeutic designed for people suffering from opioid use disorder, is under review […]
Pear Therapeutics raises $50m for digital substance use disorder therapies
Pear Therapeutics said today that it closed a $50 million Series B round to help commercialize its prescription digital substance abuse therapies. Temasek led the round and was joined by 5AM Ventures, Jazz Venture Partners, Novartis (NYSE:NVS) and others. In September, the company’s reSET therapy became the first prescription digital therapeutic approved by the FDA. One month later, […]
FDA taps Apple, J&J and others for health software pre-cert pilot
The FDA yesterday named the nine companies that will be included in a pilot program to pre-certify healthcare software developers. The program was designed with the hopes of reducing the amount of information the regulatory watchdog requires for review. The companies include Apple (NSDQ:AAPL), Fitbit (NYSE:FIT), Johnson & Johnson (NYSE:JNJ), Pear Therapeutics, Phosphorus, Roche (OTC:RHHBY), Samsung, Tidepool and Verily. […]